Table 3.
Self controlled case series analysis for orlistat use and risk of liver injury
| Variables | Patient years | No of events | Age adjusted rate ratio (95% CI) |
|---|---|---|---|
| Definite and probable cases (n=988) | |||
| Primary analyses: | |||
| Absence of orlistat | 8872 | 852 | — |
| 90 days before prescription | 241 | 42 | 1.50 (1.10 to 2.06) |
| 1-30 days orlistat | 81 | 21 | 2.21 (1.43 to 3.42) |
| 31-60 days orlistat | 80 | 10 | 1.06 (0.57 to 1.99) |
| 61-90 days orlistat | 78 | 12 | 1.32 (0.75 to 2.34) |
| >90 days orlistat | 986 | 51 | 0.78 (0.58 to 1.05) |
| Secondary analyses: | |||
| 90 days before prescription | 241 | 42 | — |
| 1-90 days orlistat | 240 | 43 | 1.02 (0.67 to 1.56) |
| 30 days before prescription | 81 | 19 | — |
| 1-30 days orlistat | 81 | 21 | 1.11 (0.59 to 2.06) |
| Definite cases (n=335) | |||
| Primary analyses: | |||
| Absence of orlistat | 3042 | 292 | — |
| 90 days before prescription | 82 | 16 | 1.75 (1.05 to 2.91) |
| 1-30 days orlistat | 27 | 1 | 0.32 (0.05 to 2.30) |
| 31-60 days orlistat | 27 | 3 | 0.97 (0.31 to 3.04) |
| 61-90 days orlistat | 26 | 6 | 2.02 (0.90 to 4.54) |
| >90 days orlistat | 211 | 17 | 0.72 (0.43 to 1.22) |
| Secondary analyses: | |||
| 90 days before prescription | 82 | 16 | — |
| 1-90 days orlistat | 81 | 10 | 0.63 (0.28 to 1.38) |
| 30 days before prescription | 27 | 5 | — |
| 1-30 days orlistat | 27 | 1 | 0.20 (0.02 to 1.71) |